Novo Nordisk shares jump 8% on U.S. Wegovy pill approval
Shares of Novo Nordisk surged nearly 8% after the U.S. FDA approved its Wegovy weight-loss pill. The landmark decision marks a major expansion for the obesity drug market.
Category : Search result: Novo Nordisk
Novo Nordisk to test obesity drug CagriSema in children
Novo Nordisk, maker of Wegovy, plans clinical trials for its experimental obesity medication CagriSema in overweight children and adolescents. Get the latest details on this significant development in pediatric health.
Novo's obesity drug shows 14.5% weight loss in trial
Novo Nordisk's experimental obesity drug amycretin demonstrates significant weight loss results in mid-stage study, advancing to late-phase testing for diabetes patients.
Novo Nordisk Alzheimer's Drug Trials Fail
Danish pharmaceutical giant Novo Nordisk faces major setback as Alzheimer's drug trials fail. Learn how this impacts the weight-loss leader's expansion plans.
Denmark compensates for Novo Nordisk vision loss
Danish authorities provide compensation to patients experiencing vision loss linked to Novo Nordisk medications. Learn about the pharmaceutical safety developments affecting Canadian consumers.
Novo Resources 2025 Sustainability Report Released
Novo Resources Corp. announces its 2025 Sustainability Report, detailing commitments to ethical governance, community development, and environmental protection in mining operations.
Novo Nordisk rolls out $349 Wegovy cash price early
Novo Nordisk introduces $349 cash price for Wegovy weight-loss drug ahead of schedule. Learn how this affects Canadian healthcare access and affordability.
Novo Resources Releases Updated Investor Presentation
Novo Resources Corp. has released an updated corporate presentation detailing its 2025 exploration milestones and strategic priorities for gold and copper projects in Australia.
High-Grade Gold & Antimony Found in Pilbara
Novo Resources reports strong gold results from Teichman and high-grade antimony from Sherlock Crossing in Western Australia's Pilbara region. Exploration continues.
Pfizer wins $10B obesity drug takeover battle
Pfizer triumphs in dramatic $10 billion bidding war for obesity drug maker Metsera, securing crucial White House-backed deal to compete in weight-loss market. Read the full story.
Trump Obesity Drug Deal Boosts Pharma Stocks
Major pharmaceutical giants Novo Nordisk and Eli Lilly experience significant stock surges as former President Donald Trump considers a groundbreaking obesity drug partnership, potentially revolutionizing weight loss treatment accessibility.
Page 1 of 1